What Aurora Cannabis Doubters Saw Before The Drop

If you only glanced at the latest Aurora Cannabis results, improving losses and a healthier net margin might look like the start of a turnaround. Holding Aurora Cannabis over the past year would have meant a 23.3% loss, including dividends. If you had been weighing those 2025 forecasts against the later bid from Curaleaf and the recent quarterly figures, what exactly was visible upfront and what only emerged once the year was already locked in?

The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.

If the move has made Aurora Cannabis harder to judge, start where the gap is still open and scan 5 high quality undervalued stocks.

The Two Stories Aurora Cannabis Investors Were Weighing

The shares cost CA$7.43 at the start of the period, and anyone looking at Aurora Cannabis then was effectively choosing between two very different but reasonable stories.

On the optimistic side, the bull Narrative put Fair Value at CA$7.92, built on the idea that international medical markets like Europe and Australia would support 5.3% annual revenue growth and a profit margin reaching 10.1% over three years.

The cautious view set Fair Value at CA$6, assuming slower 4.8% revenue growth and warning that regulatory uncertainty and rising competition could cap margins around 1.2% and justify a future P/E of 87.7x.

What The Results Changed For Aurora Cannabis

The board urging investors to reject Curaleaf's hostile offer leaned toward the bull story, because it argued Aurora Cannabis had stronger cash and prospects than the bid implied. The latest quarter then cut both ways. Revenue slipped from CA$74.076m to CA$67.554m, yet the loss narrowed from CA$10.186m to CA$4.033m and net margin improved from -13.8% to -6.0%. Profitability targets remained unproven.

The key assumption here was margin repair, not just top line ambition. When assessing another company, track whether net income and net margin are moving toward the forecast level that underpins any growth or P/E story.

What Aurora Cannabis Buyers Are Being Asked To Believe Now

Aurora Cannabis trades at CA$5.64 today, after a share price that declined 23.3% over the past year. The selected Narrative still places Fair Value above that level and anchors its case in global medical exposure rather than domestic recreational recovery.

That higher Fair Value depends on Aurora Cannabis converting its regulatory know how and medical focus into sustained, higher margin international sales over time.

"While analyst consensus recognizes Aurora's GMP-certified facilities and global medical expansion as drivers of revenue growth, this likely understates Aurora's potential to secure an outsized share of new international markets due to its decade-long regulatory expertise and entrenched relationships, which could significantly accelerate both top-line growth and market share capture faster than competitors expect."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Aurora Cannabis And Another Angle

Looking at Aurora Cannabis means studying one specific regulated health story. There is another route close by.

Where Aurora focuses on cannabis and medical access, this other business concentrates on broader biopharmaceutical treatments for major diseases.

It develops vaccines and specialty medicines that address chronic conditions, rare disorders and some cancers.

Both operate under tight regulation and pricing pressure, yet their scientific approaches and revenue mix differ significantly.

If you are weighing Aurora Cannabis, it might be worth asking how that broader drug pipeline story compares.

The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 22% above its price

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com